PALI-2108 Phase 1a/b Data Shows Sustained Efficacy, Once-Daily Dosing Potential for Ulcerative Colitis
Summary
Palisade Bio announced additional positive Phase 1a/b data for its lead ulcerative colitis candidate, PALI-2108. The data demonstrated a differentiated pharmacokinetic profile with colon-targeted exposure and sustained active metabolite concentrations above the IC90 threshold, supporting once-daily dosing. These findings build on previously reported positive clinical, histological, and biomarker improvements, including 100% clinical response in patients. For a clinical-stage biopharmaceutical company, this strong early-stage data significantly de-risks the asset and validates its potential as a convenient, effective oral therapy for ulcerative colitis. This positive development is crucial for advancing PALI-2108 into later-stage trials and could attract significant investor or partnership interest. Investors should monitor the company's plans for further clinical development and potential financing activities.
At the time of this announcement, PALI was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $356.6M. The 52-week trading range was $0.53 to $2.86. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.